Thunder Biotech is a pre-clinical oncology company developing a complete solution for the detection, treatment, and monitoring of patient tumors. We have developed a novel immunotherapy to target unique biomarkers expressed on the surface of malignant tumors. In addition, we have developed a companion diagnostic assay to detect various stages of cancer and to monitor potential recurrence.
Using Chimeric Antigen Receptor (CAR) technology, we genetically modify T-cells to target cancer cells expressing unique biomarkers. Additionally, we have developed a novel immunotherapy involving other immune cells – MOTO-CARs™.
Our goal is to provide cancer patients with a more effective treatment while avoiding the adverse side effects of traditional treatments. We envision an immediate future where our diagnostic assay will accurately detect the presence and stage of cancer, and our adoptive immunotherapy will effectively boost the immune system to recognize and destroy the cancer cells.
The Thunder Biotech team consists of scientists, healthcare professionals, and opinion leaders in the immune-oncology field. The management team and its advisory board members are driven by a passion to bring a complete solution to the early detection and treatment of cancer.
Business Advisory Board
“We have developed a novel method of activating the immune system to target unique cancer biomarkers. Using CAR technology, we can genetically modify immune cells to recognized and destroy malignant tumor cells.”